{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:59:25Z","timestamp":1790776765528,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01710-9","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:26:19Z","timestamp":1790774779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Intrinsic Factors on the Pharmacokinetics of Once-Weekly Insulin Icodec in Type 1 and Type 2 Diabetes: A Population Pharmacokinetic Analysis of Phase II and Phase III trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-6298","authenticated-orcid":false,"given":"Niels R.","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mundot P.","family":"Haridas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Philis-Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Ribel-Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1710_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/nature08933","volume":"464","author":"JA Bluestone","year":"2010","unstructured":"Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293\u2013300. https:\/\/doi.org\/10.1038\/nature08933.","journal-title":"Nature"},{"key":"1710_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2337\/ds18-0005","volume":"32","author":"J Chun","year":"2019","unstructured":"Chun J, Strong J, Urquhart S. Insulin initiation and titration in patients with type 2 diabetes. Diabetes Spectr. 2019;32:104\u201311. https:\/\/doi.org\/10.2337\/ds18-0005.","journal-title":"Diabetes Spectr"},{"key":"1710_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2337\/ds22-0084","volume":"36","author":"JR Gavin","year":"2023","unstructured":"Gavin JR, Abaniel RM, Virdi NS. Therapeutic inertia and delays in insulin intensification in type 2 diabetes: a literature review. Diabetes Spectr. 2023;36:379\u201384. https:\/\/doi.org\/10.2337\/ds22-0084.","journal-title":"Diabetes Spectr"},{"key":"1710_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1463-1326.2010.01327.x","volume":"13","author":"WH Polonsky","year":"2011","unstructured":"Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144\u20139. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01327.x.","journal-title":"Diabetes Obes Metab"},{"key":"1710_CR5","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1021\/acs.jmedchem.1c00257","volume":"64","author":"TB Kjeldsen","year":"2021","unstructured":"Kjeldsen TB, Hub\u00e1lek F, Hj\u00f8rringgaard CU, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem. 2021;64:8942\u201350. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00257.","journal-title":"J Med Chem"},{"key":"1710_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002301","volume":"9","author":"E Nishimura","year":"2021","unstructured":"Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9:e002301. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002301.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1710_CR7","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1111\/dom.15266","volume":"25","author":"TR Pieber","year":"2023","unstructured":"Pieber TR, Asong M, Fluhr G, et al. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes. Diabetes Obes Metab. 2023;25:3716\u201323. https:\/\/doi.org\/10.1111\/dom.15266.","journal-title":"Diabetes Obes Metab"},{"key":"1710_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/dom.15510","volume":"26","author":"U H\u00f6velmann","year":"2024","unstructured":"H\u00f6velmann U, Engberg S, Heise T, et al. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. 2024;26:1941\u20139. https:\/\/doi.org\/10.1111\/dom.15510.","journal-title":"Diabetes Obes Metab"},{"key":"1710_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJMoa2303208","volume":"389","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389:297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2303208.","journal-title":"N Engl J Med"},{"key":"1710_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-8587(23)00093-1","volume":"11","author":"A Philis-Tsimikas","year":"2023","unstructured":"Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414\u201325. https:\/\/doi.org\/10.1016\/S2213-8587(23)00093-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1710_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jama.2023.11313","volume":"330","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330:228\u201337. https:\/\/doi.org\/10.1001\/jama.2023.11313.","journal-title":"JAMA"},{"key":"1710_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(23)00520-2","volume":"401","author":"C Mathieu","year":"2023","unstructured":"Mathieu C, \u00c1sbj\u00f6rnsd\u00f3ttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(23)00520-2.","journal-title":"Lancet"},{"key":"1710_CR13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.7326\/M23-1288","volume":"176","author":"HS Bajaj","year":"2023","unstructured":"Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023;176:1476\u201385. https:\/\/doi.org\/10.7326\/M23-1288.","journal-title":"Ann Intern Med"},{"key":"1710_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0140-6736(23)02179-7","volume":"402","author":"D Russell-Jones","year":"2023","unstructured":"Russell-Jones D, Babazono T, Cailleteau R, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet. 2023;402:1636\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(23)02179-7.","journal-title":"Lancet"},{"key":"1710_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/antib11010001","volume":"11","author":"I Mahmood","year":"2021","unstructured":"Mahmood I, Pettinato M. Impact of intrinsic and extrinsic factors on the pharmacokinetics of peptides: when is the assessment of certain factors warranted? Antibodies. 2021;11:1. https:\/\/doi.org\/10.3390\/antib11010001.","journal-title":"Antibodies"},{"key":"1710_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6\u201314. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.02007.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1710_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/jdi.14384","volume":"16","author":"T Eto","year":"2025","unstructured":"Eto T, Haranaka M, Kristensen NR, et al. Pharmacological characteristics of once-weekly insulin icodec in Japanese individuals with type 1 diabetes. J Diabetes Investig. 2025;16:434\u201341. https:\/\/doi.org\/10.1111\/jdi.14384.","journal-title":"J Diabetes Investig"},{"key":"1710_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/jdi.70005","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Fu A, Jiang S, et al. Pharmacokinetic properties of once-weekly insulin icodec in Chinese individuals with type 2 diabetes. J Diabetes Investig. 2025;16:639\u201345. https:\/\/doi.org\/10.1111\/jdi.70005.","journal-title":"J Diabetes Investig"},{"key":"1710_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/pedi\/5514927","author":"M Van Name","year":"2025","unstructured":"Van Name M, \u00c1sbj\u00f6rnsd\u00f3ttir B, Gomes MM, et al. Pharmacokinetic properties of once-weekly insulin icodec in children and adolescents with type 2 diabetes. Pediatr Diabetes. 2025. https:\/\/doi.org\/10.1155\/pedi\/5514927.","journal-title":"Pediatr Diabetes"},{"key":"1710_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40262-024-01375-2","volume":"63","author":"H Haahr","year":"2024","unstructured":"Haahr H, Cieslarov\u00e1 B, Hingst JR, et al. The effect of various degrees of renal or hepatic impairment on the pharmacokinetic properties of once-weekly insulin icodec. Clin Pharmacokinet. 2024;63:819\u201330. https:\/\/doi.org\/10.1007\/s40262-024-01375-2.","journal-title":"Clin Pharmacokinet"},{"key":"1710_CR21","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","volume":"383","author":"J Rosenstock","year":"2020","unstructured":"Rosenstock J, Bajaj HS, Jane\u017e A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383:2107\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2022474.","journal-title":"N Engl J Med"},{"key":"1710_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-022-01243-6","volume":"43","author":"L Plum-M\u00f6rschel","year":"2023","unstructured":"Plum-M\u00f6rschel L, Andersen LR, Hansen S, et al. Pharmacokinetic and pharmacodynamic characteristics of insulin icodec after subcutaneous administration in the thigh, abdomen or upper arm in individuals with type 2 diabetes mellitus. Clin Drug Investig. 2023;43:119\u201327. https:\/\/doi.org\/10.1007\/s40261-022-01243-6.","journal-title":"Clin Drug Investig"},{"key":"1710_CR23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1177\/0091270008318670","volume":"48","author":"C Hu","year":"2008","unstructured":"Hu C, Zhou H. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol. 2008;48:812\u201322. https:\/\/doi.org\/10.1177\/0091270008318670.","journal-title":"J Clin Pharmacol"},{"key":"1710_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pst.403","volume":"10","author":"C Hu","year":"2011","unstructured":"Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2011;10:14\u201326. https:\/\/doi.org\/10.1002\/pst.403.","journal-title":"Pharm Stat"},{"key":"1710_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369. https:\/\/doi.org\/10.1208\/s12248-009-9133-0.","journal-title":"AAPS J"},{"key":"1710_CR26","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","volume":"24","author":"AC Hooker","year":"2007","unstructured":"Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187\u201397. https:\/\/doi.org\/10.1007\/s11095-007-9361-x.","journal-title":"Pharm Res"},{"key":"1710_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"1710_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1710_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1710_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Programs Biomed"},{"key":"1710_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Programs Biomed"},{"key":"1710_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2165\/11631630-000000000-00000","volume":"51","author":"I Mahmood","year":"2012","unstructured":"Mahmood I. Prediction of clearance and volume of distribution in the obese from normal weight subjects: an allometric approach. Clin Pharmacokinet. 2012;51:527\u201342. https:\/\/doi.org\/10.2165\/11631630-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1710_CR33","unstructured":"Awiqli (insulin icodec). Summary of product characteristics. European Medicines Agency. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/awiqli-epar-product-information_en.pdf. Accessed 1 Sept 2026."},{"key":"1710_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.eprac.2024.11.009","volume":"31","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, \u00c1sbj\u00f6rnsd\u00f3ttir B, Kristensen NR, Laugesen C, Vianna A, Knop FK. Pharmacokinetic\/pharmacodynamic modeling of efficacy and hypoglycemia rate when switching from once-daily basal insulin to once-weekly insulin icodec without or with a one-time additional dose in insulin-experienced individuals with type 2 diabetes. Endocr Pract. 2025;31:147\u201351. https:\/\/doi.org\/10.1016\/j.eprac.2024.11.009.","journal-title":"Endocr Pract"},{"key":"1710_CR35","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1111\/dom.15960","volume":"26","author":"H Watada","year":"2024","unstructured":"Watada H, \u00c1sbj\u00f6rnsd\u00f3ttir B, Nishida T, et al. Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: a subgroup analysis of the ONWARDS 1, 2 and 4 trials. Diabetes Obes Metab. 2024;26:5882\u201395. https:\/\/doi.org\/10.1111\/dom.15960.","journal-title":"Diabetes Obes Metab"},{"key":"1710_CR36","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13300-025-01701-2","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Kar S, Li C, et al. Once-weekly insulin icodec versus once-daily insulin degludec in insulin-naive Chinese participants with type 2 diabetes: a post hoc analysis of ONWARDS 3. Diabetes Ther. 2025;16:685\u201399. https:\/\/doi.org\/10.1007\/s13300-025-01701-2.","journal-title":"Diabetes Ther"},{"key":"1710_CR37","doi-asserted-by":"publisher","first-page":"e3596","DOI":"10.1210\/clinem\/dgaf168","volume":"110","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Bache JK, Desouza CV, et al. Efficacy and hypoglycemia profile of once-weekly insulin icodec vs. once-daily comparators across demographic subgroups. J Clin Endocrinol Metab. 2025;110:e3596\u2013606. https:\/\/doi.org\/10.1210\/clinem\/dgaf168.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01710-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:26:21Z","timestamp":1790774781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01710-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":37,"alternative-id":["1710"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01710-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Novo Nordisk.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Niels R. Kristensen, Mundot P. Haridas and Rasmus Ribel-Madsen are employees and shareholders of Novo Nordisk. Athena Philis-Tsimikas performs research and serves as an adviser for AbbVie, Dexcom, Eli Lilly, Medtronic, Novo Nordisk and Structure. Chantal Mathieu serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB Bio and Vertex. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for Chantal Mathieu from Medtronic, Novo Nordisk and Sanofi. Chantal Mathieu serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. Chantal Mathieu is Chair of the Board of the European Diabetes Forum (EUDF). All external support of EUDF can be found on\n                      \n                      .","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trials were approved by the respective local independent ethics committees and were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. For details, please refer to the original publications [\n                      \n                      \u2013\n                      \n                      ,\n                      \n                      ,\n                      \n                      ].","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the clinical trials.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Individual participant data will be shared in data sets in a de-identified\/anonymised format. Data sets from Novo Nordisk-sponsored clinical research completed after 2001 for product indications approved in both the European Union and USA will be shared. Trial protocols and redacted clinical trial reports will be available according to Novo Nordisk data sharing commitments. The data will be available permanently after research completion and approval of product and product use in both the European Union and the USA. There is no end date. Data will be shared with bona fide researchers submitting a research proposal requesting access to data for use as approved by the Independent Review Board according to the Independent Review Board Charter (see novonordisk-trials.com). The data will be made available on a specialised SAS data platform.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NRK contributed with data analysis, data interpretation, drafting the manuscript, critical manuscript revision and final manuscript approval. MPH and RR-M contributed with data interpretation, critical manuscript revision and final manuscript approval. AP-T and CM contributed with data collection, data interpretation, critical manuscript revision and final manuscript approval.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}